SCHEMBL26118348

SCHEMBL26118348

Oc1cccc(Nc2nnc(Cl)c3ccccc23)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.64
NPSR1 Q6W5P4 2/20 0.64
KDR P35968 2/20 0.57
PDGFRB P09619 1/20 0.57
KIT P10721 1/20 0.57
FLT1 P17948 1/20 0.57
GLA P06280 1/20 0.54
HTT P42858 1/20 0.54
BRAF P15056 1/20 0.53
SMN1; SMN2 Q16637 3/20 0.51
CYP3A4 P08684 2/20 0.51
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
KDM4E B2RXH2 1/20 0.51
PDE5A O76074 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
ALOX15 P16050 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31359772 1.00 MAPT (0.64) MAPTNPSR1KDRPDGFRBKIT
SCHEMBL26117529 0.85 KDR (0.52) MAPTNPSR1KDRPDGFRBKIT
SCHEMBL31359777 0.85 KDR (0.52) MAPTNPSR1KDRPDGFRBKIT
SCHEMBL31359729 0.85 KDR (0.55) MAPTNPSR1KDRPDGFRBKIT
SCHEMBL26117847 0.85 KDR (0.55) MAPTNPSR1KDRPDGFRBKIT
SCHEMBL4738808 0.84 PDE5A (0.69) MAPTKDRSMN1; SMN2CYP3A4ALDH1A1
SCHEMBL10338919 0.82 GOT1 (0.61) MAPTNPSR1KDRPDGFRBKIT
SCHEMBL7918654 0.79 MAPT (0.87) MAPTNPSR1KDRPDGFRBKIT
SCHEMBL6496240 0.76 KDR (0.58) KDRPDGFRBKITFLT1SMN1; SMN2
SCHEMBL25300791 0.75 ALDH1A1 (0.50) MAPTNPSR1KDRFLT1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250340563-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS TAKEDA DEVELOPMENT CENTER AMERICAS, INC. 2025-11-06 US disclosed
EP-4504733-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2025-02-12 EP disclosed
WO-2023194964-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-12 WO disclosed
WO-2023194964-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250340563-A1 FUSED PYRIDAZINE DERIVATIVES AS NLRP3 INHIBITORS NLRP3, NLRP1, NOD1 MAPT 1282/4885NPSR1 1896/4885KDR 3812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.